Literature DB >> 33053563

The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative SARM1.

Yuefeng Jiang1, Tingting Liu1, Chia-Hsueh Lee2, Qing Chang3, Jing Yang4, Zhe Zhang5.   

Abstract

Pathological degeneration of axons disrupts neural circuits and represents one of the hallmarks of neurodegeneration1-4. Sterile alpha and Toll/interleukin-1 receptor motif-containing protein 1 (SARM1) is a central regulator of this neurodegenerative process5-8, and its Toll/interleukin-1 receptor (TIR) domain exerts its pro-neurodegenerative action through NADase activity9,10. However, the mechanisms by which the activation of SARM1 is stringently controlled are unclear. Here we report the cryo-electron microscopy structures of full-length SARM1 proteins. We show that NAD+ is an unexpected ligand of the armadillo/heat repeat motifs (ARM) domain of SARM1. This binding of NAD+ to the ARM domain facilitated the inhibition of the TIR-domain NADase through the domain interface. Disruption of the NAD+-binding site or the ARM-TIR interaction caused constitutive activation of SARM1 and thereby led to axonal degeneration. These findings suggest that NAD+ mediates self-inhibition of this central pro-neurodegenerative protein.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33053563     DOI: 10.1038/s41586-020-2862-z

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  49 in total

Review 1.  Wallerian degeneration, wld(s), and nmnat.

Authors:  Michael P Coleman; Marc R Freeman
Journal:  Annu Rev Neurosci       Date:  2010       Impact factor: 12.449

2.  SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.

Authors:  Josiah Gerdts; E J Brace; Yo Sasaki; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Science       Date:  2015-04-23       Impact factor: 47.728

3.  The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.

Authors:  Kow Essuman; Daniel W Summers; Yo Sasaki; Xianrong Mao; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Neuron       Date:  2017-03-22       Impact factor: 17.173

Review 4.  Signaling mechanisms regulating Wallerian degeneration.

Authors:  Marc R Freeman
Journal:  Curr Opin Neurobiol       Date:  2014-06-05       Impact factor: 6.627

5.  Sarm1-mediated axon degeneration requires both SAM and TIR interactions.

Authors:  Josiah Gerdts; Daniel W Summers; Yo Sasaki; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  J Neurosci       Date:  2013-08-14       Impact factor: 6.167

6.  dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.

Authors:  Jeannette M Osterloh; Jing Yang; Timothy M Rooney; A Nicole Fox; Robert Adalbert; Eric H Powell; Amy E Sheehan; Michelle A Avery; Rachel Hackett; Mary A Logan; Jennifer M MacDonald; Jennifer S Ziegenfuss; Stefan Milde; Ying-Ju Hou; Carl Nathan; Aihao Ding; Robert H Brown; Laura Conforti; Michael Coleman; Marc Tessier-Lavigne; Stephan Züchner; Marc R Freeman
Journal:  Science       Date:  2012-06-07       Impact factor: 47.728

7.  Pathological axonal death through a MAPK cascade that triggers a local energy deficit.

Authors:  Jing Yang; Zhuhao Wu; Nicolas Renier; David J Simon; Kunihiro Uryu; David S Park; Peter A Greer; Cathy Tournier; Roger J Davis; Marc Tessier-Lavigne
Journal:  Cell       Date:  2015-01-15       Impact factor: 41.582

Review 8.  Wallerian degeneration: an emerging axon death pathway linking injury and disease.

Authors:  Laura Conforti; Jonathan Gilley; Michael P Coleman
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

9.  MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2.

Authors:  Lauren J Walker; Daniel W Summers; Yo Sasaki; E J Brace; Jeffrey Milbrandt; Aaron DiAntonio
Journal:  Elife       Date:  2017-01-17       Impact factor: 8.140

Review 10.  Programmed axon degeneration: from mouse to mechanism to medicine.

Authors:  Michael P Coleman; Ahmet Höke
Journal:  Nat Rev Neurosci       Date:  2020-03-09       Impact factor: 34.870

View more
  43 in total

Review 1.  SARM1 can be a potential therapeutic target for spinal cord injury.

Authors:  Qicheng Lu; Benson O A Botchway; Yong Zhang; Tian Jin; Xuehong Liu
Journal:  Cell Mol Life Sci       Date:  2022-02-28       Impact factor: 9.261

2.  Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection.

Authors:  Yo Sasaki; Jian Zhu; Yun Shi; Weixi Gu; Bostjan Kobe; Thomas Ve; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Exp Neurol       Date:  2021-08-14       Impact factor: 5.330

3.  Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss.

Authors:  Tong Wu; Jian Zhu; Amy Strickland; Kwang Woo Ko; Yo Sasaki; Caitlin B Dingwall; Yurie Yamada; Matthew D Figley; Xianrong Mao; Alicia Neiner; A Joseph Bloom; Aaron DiAntonio; Jeffrey Milbrandt
Journal:  Cell Rep       Date:  2021-10-19       Impact factor: 9.423

4.  SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration.

Authors:  Matthew D Figley; Weixi Gu; Jeffrey D Nanson; Yun Shi; Yo Sasaki; Katie Cunnea; Alpeshkumar K Malde; Xinying Jia; Zhenyao Luo; Forhad K Saikot; Tamim Mosaiab; Veronika Masic; Stephanie Holt; Lauren Hartley-Tassell; Helen Y McGuinness; Mohammad K Manik; Todd Bosanac; Michael J Landsberg; Philip S Kerry; Mehdi Mobli; Robert O Hughes; Jeffrey Milbrandt; Bostjan Kobe; Aaron DiAntonio; Thomas Ve
Journal:  Neuron       Date:  2021-03-02       Impact factor: 17.173

5.  Genetic inactivation of SARM1 axon degeneration pathway improves outcome trajectory after experimental traumatic brain injury based on pathological, radiological, and functional measures.

Authors:  Donald V Bradshaw; Andrew K Knutsen; Alexandru Korotcov; Genevieve M Sullivan; Kryslaine L Radomski; Bernard J Dardzinski; Xiaomei Zi; Dennis P McDaniel; Regina C Armstrong
Journal:  Acta Neuropathol Commun       Date:  2021-05-17       Impact factor: 7.801

Review 6.  A Novel NAD Signaling Mechanism in Axon Degeneration and its Relationship to Innate Immunity.

Authors:  Eleanor L Hopkins; Weixi Gu; Bostjan Kobe; Michael P Coleman
Journal:  Front Mol Biosci       Date:  2021-07-08

Review 7.  Targeting Diet and Exercise for Neuroprotection and Neurorecovery in Glaucoma.

Authors:  James R Tribble; Flora Hui; Melissa Jöe; Katharina Bell; Vicki Chrysostomou; Jonathan G Crowston; Pete A Williams
Journal:  Cells       Date:  2021-02-01       Impact factor: 6.600

Review 8.  NAD+ Metabolism, Metabolic Stress, and Infection.

Authors:  Benjamin Groth; Padmaja Venkatakrishnan; Su-Ju Lin
Journal:  Front Mol Biosci       Date:  2021-05-19

Review 9.  The Influence of Mitochondrial Dynamics and Function on Retinal Ganglion Cell Susceptibility in Optic Nerve Disease.

Authors:  Nicole A Muench; Sonia Patel; Margaret E Maes; Ryan J Donahue; Akihiro Ikeda; Robert W Nickells
Journal:  Cells       Date:  2021-06-25       Impact factor: 6.600

10.  A phase transition enhances the catalytic activity of SARM1, an NAD+ glycohydrolase involved in neurodegeneration.

Authors:  Heather S Loring; Victoria L Czech; Janneke D Icso; Lauren O'Connor; Sangram S Parelkar; Alexandra B Byrne; Paul R Thompson
Journal:  Elife       Date:  2021-06-29       Impact factor: 8.140

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.